Abstract:OBJECTIVE:To explore the pathogenesis mechanism of hypertrophic scar (HS) and the effective means for its clinical treatment, the difference of the gene expressions between HS and normal skin was compared.METHODS:The differentially expressed genes between HS and normal skin were obtained by mining PubMed. The dysregulated genes in HS were analyzed by a series of bioinformatics methods, including protein-protein interaction networks, pathways, Gene Ontology and functional annotation clustering analysis.RESULTS:A total of 55 dysregulated genes in HS was identified (46 up-regulated genes and 9 down-regulated genes). Fifty-one genes were found to encode proteins with interaction network, including up-regulated genes TGFB1, FN1, JUN, COL1A1, CTGF, VEGFA, FOS, COL3A1, IGF1, IL4, PELO, SMAD2, TIMP1, PCNA, and ITGA4 and down-regulated genes ITGB1 and DCN as the central nodes for this network. The dysregulated genes in HS involved in a variety of biological pathways, such as focal adhesion formation, integrin signal transduction, and tumor formation. Furthermore, the dysregulated genes in HS played the important roles in biological processes of cell surface receptor linked signal transduction, tissue development, cell proliferation and apoptosis, and macromolecule biosynthetic process, as well as in molecular function of calcium ion binding, double-stranded DNA binding, heparin binding, promoter binding and MAP kinase activity. The results of functional annotation clustering analysis revealed that the dysregulated genes in HS involved in epidermis development, angiogenesis, and apoptosis.CONCLUSION:Such key genes as TGFB1, FN1, and JUN, along with the pathways, biological processes and molecular functions involving epidermis development, angiogenesis, and extracellular matrix-integrin-focal adhesion signal transduction may play the important roles in the development of HS. The investigations of the dysregulated genes in HS could provide the new targets for clinical treatment.

Research progress of renin angiotensin system on hypertrophic scar

Angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor blocker: Potential agents to reduce post-surgical scar formation in humans

Research progress of topical anti-scar agents

The Effect of Topical Ramipril and Losartan Cream in Inhibiting Scar Formation

[Research advances on pharmacological interventions for hypertrophic scar]

Adenovirus-mediated METH1 gene expression inhibits hypertrophic scarring in a rabbit ear model.

Angiotensin-converting Enzyme Inhibitor Reduces Scar Formation by Inhibiting Both Canonical and Noncanonical TGF-β1 Pathways

Insights into the role of adipose-derived stem cells and secretome: potential biology and clinical applications in hypertrophic scarring

Exploring the Molecular Underpinnings of Skin Regeneration and Wound Healing: The Role of Renin Angiotensin

Fibroblasts and endothelial cells interplay drives hypertrophic scar formation: Insights from in vitro and in vivo models

The regulatory role of the apelin/APJ axis in scarring: Identification of upstream and downstream mechanisms

Emerging Role of IL-10 in Hypertrophic Scars

The Link Between Hypertension and Pathological Scarring: Does Hypertension Cause or Promote Keloid and Hypertrophic Scar Pathogenesis?

Keloids and hypertrophic scars: update and future directions.

Current potential therapeutic strategies targeting the TGF-β/Smad signaling pathway to attenuate keloid and hypertrophic scar formation

Molecular mechanism of myofibroblast formation and strategies for clinical drugs treatments in hypertrophic scars

Systemic factors that shape cutaneous pathological scarring

[Literature Mining and Bioinformatic Analysis of Dysregulated Genes in Hypertrophic Scar].

Natural products for the treatment of hypertrophic scars: Preclinical and clinical studies

Using network pharmacology to discover potential drugs for hypertrophic scars

miR-155 inhibits the formation of hypertrophic scar fibroblasts by targeting HIF-1α via PI3K/AKT pathway